Chronic Heart Failure, Chronic Renal Failure
Conditions
Interventions
Tolvaptane combination group: furosemide at a dose of 120mg daily for 3 days given in combination with tolvaptan 15mg/day
Conventional treatment group: furosemide at a dose of 120mg daily for 3 days
Sponsors
Division of Kidney and Hypertension, the Jikei University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)The patients with chronic heart failure 2)The patients undergoing peritoneal dialysis 3)The admitted patients 4)Male and Female 5)The patients over 20 years old in a time of consent 6)The patients with individual or representitive consent
Exclusion criteria
Exclusion criteria: 1)The patients showing allergy to tolvaptan or similar compound (ex. mozavaptan) 2)The patients showing allergy to sulfonamide 3)The anuric patients 4)The patients without a sense of thirst or ability to intake water 5)The patients with hypernatremia 6)The pregnant patients 7)The patients taking tolvaptan at the time of enrolling 8)The patitents in need of emergency medical care for massive heart failure 9)The patients given furosemide over 120mg/day at the time of enrolling 10)The patients with hepatic coma 11)The patients regarded as inappropriate for this clinical study by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of Body Weight | — |
Secondary
| Measure | Time frame |
|---|---|
| urine volume, urine osmolarity, serum osmolarity, serum electrolyte concentration, hANP, BNP, fluid retention, water intake, NYHA functional classification, serum ADH, creatinine clearance, urine electrolyte concentration, total removed fluid with PD | — |
Countries
Japan
Contacts
Public ContactHiroshi Hayakawa M.D., Ph.D.
The Jikei University School of Medicine Division of Kidney and Hypertension
Outcome results
None listed